Kite Pharma

Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma patients, later this year. Kite is pursuing an FDA label for patients with relapsed, aggressive and non-transplant eligible forms of the disease, a group of...

Shares of Kite Pharma Inc (NASDAQ: KITE) were trading higher by more than 2 percent early Wednesday morning after the company's management provided an update on an ongoing Phase 1 trial at an industry conference. Kite Pharma's management spoke at the American Association of Cancer Research's annual...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have gained more nearly 30 percent over the past three months, but are lower by more than 10 percent over the past five days. Despite recent weakness in Juno's stock, the Vetr crowd upgraded the issue to four stars out of a possible five...

Since it hit a 52-week high on May 29, bluebird bio Inc (NASDAQ: BLUE) is more than 18 percent lower. Debjit Chattopadhyay, an analyst with Roth Capital Partners, said that given this correction, it is now time to buy the dip. Heading into the American Society of Hematology meeting in Q4, Roth...

"Biotech is booming," says LifeSci Capital co-founder and co-manager of the BioShares exchange traded funds, Andrew McDonald. McDonald, along with fellow LifeSci co-founder Paul Yook, spoke with Benzinga about innovations in biotech and how investors might take advantage. BZ: What...

Kite Pharma Inc (NASDAQ: KITE) is trading higher on Wednesday after the company presented at the 2015 Jefferies Now at the Immuno-Oncology Summit in Boston. The company has been a solid performer in 2015, and is up 120 percent in the past year. In the presentation, Kite Pharma discussed everything...